

Valentina Svicher

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3533830/valentina-svicher-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

111
papers

2,043
citations

27
h-index

38
g-index

117
ext. papers

2,374
ext. citations

6.1
avg, IF

4.07
L-index

#	Paper	IF	Citations
111	First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario?. <i>Microorganisms</i> , 2022 , 10,	4.9	2
110	Human Monocyte-Derived Macrophages (MDM): Model 1 (GM-CSF).. <i>Methods in Molecular Biology</i> , 2022 , 2407, 91-96	1.4	1
109	Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.. <i>Microbiology Spectrum</i> , 2022 , e0273221	8.9	6
108	Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2021 , 70, 2337-2348	19.2	14
107	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. <i>Microbiology Spectrum</i> , 2021 , e0109621	8.9	9
106	The impact of DAA-mediated HCV eradication on CD4 and CD8 T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 779-786	3.4	2
105	An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression. <i>Microorganisms</i> , 2021 , 9,	4.9	1
104	Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment. <i>Methods</i> , 2021 ,	4.6	3
103	Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 396-412	5.1	6
102	Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers. <i>Scientific Reports</i> , 2021 , 11, 3965	4.9	1
101	HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort. <i>Microorganisms</i> , 2021 , 9,	4.9	2
100	Crucial Role of Central Nervous System as a Viral Anatomical Compartment for HIV-1 Infection.. <i>Microorganisms</i> , 2021 , 9,	4.9	1
99	Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages. <i>Virulence</i> , 2020 , 11, 400-413	4.7	5
98	Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1778-1786	5.1	6
97	A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro. <i>Viruses</i> , 2020 , 12,	6.2	4
96	Successful ongoing retreatment with glecaprevir/pibrentasvir± sofosbuvir± ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1266-1268	9.5	2
95	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. <i>Drug Resistance Updates</i> , 2020 , 53, 100721	23.2	44

94	Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. <i>Microorganisms</i> , 2020 , 8,	4.9	3
93	Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis. <i>Life</i> , 2020 , 10,	3	6
92	Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels , hinder HBsAg secretion and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. <i>Emerging Microbes and Infections</i> , 2020 , 9, 928-939	18.9	3
91	New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts. <i>Viruses</i> , 2019 , 11,	6.2	7
90	HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy. <i>Scientific Reports</i> , 2019 , 9, 11942	4.9	8
89	Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report. <i>Journal of Medical Case Reports</i> , 2019 , 15, 2000	1.2	2
88	Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success. <i>Journal of Clinical Virology</i> , 2019 , 117, 61-67	14.5	13
87	A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 846-855	3.4	8
86	Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. <i>Virus Genes</i> , 2019 , 55, 290-297	2.3	
85	CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy. <i>Molecules</i> , 2019 , 24,	4.8	14
84	Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation. <i>Journal of Infectious Diseases</i> , 2019 , 220, 1935-1939	7	4
83	Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage. <i>Medicina (Lithuania)</i> , 2019 , 55,	3.1	11
82	Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofy356	1	31
81	The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 906.e1-906.e7	9.5	8
80	Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. <i>BMC Infectious Diseases</i> , 2018 , 18, 251	4	20
79	HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. <i>Viruses</i> , 2018 , 10,	6.2	3
78	High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance. <i>PLoS ONE</i> , 2018 , 13, e0195045	3.7	9
77	Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. <i>Scientific Reports</i> , 2018 , 8, 15739	4.9	0

76	The degree of HIV-1 amino acid variability is strictly related to different disease progression rates. <i>Virus Genes</i> , 2018 , 54, 493-501	2.3	2
75	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017 , 37, 514-528	7.9	71
74	Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS Ampliprep/COBASTaqMan HBV test v2.0. <i>Medical Microbiology and Immunology</i> , 2017 , 206, 295-299	4	
73	Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages. <i>Viruses</i> , 2017 , 9,	6.2	9
72	The Role of HIV Infection in Neurologic Injury. <i>Brain Sciences</i> , 2017 , 7,	3.4	23
71	Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. <i>Oncotarget</i> , 2017 , 8, 15704-15715	3.3	7
70	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. <i>AIDS Reviews</i> , 2017 , 19,	1.5	3
69	Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). <i>Journal of Infectious Diseases</i> , 2016 , 213, 39-48	7	25
68	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 739-50	5.1	12
67	Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy. <i>Aids</i> , 2016 , 30, 731-41	3.5	8
66	Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B. <i>Journal of Infectious Diseases</i> , 2016 , 213, 1897-905	7	33
65	Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression. <i>Liver Transplantation</i> , 2016 , 22, 1205-13	4.5	17
64	The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro. <i>Journal of Global Antimicrobial Resistance</i> , 2016 , 7, 1-7	3.4	2
63	48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study. <i>New Microbiologica</i> , 2016 , 39, 192-196	1.1	1
62	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 2935-41	9.7	4
61	HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1865-73	5.1	19
60	A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 1124.e1-4	9.5	3
59	Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4870-81	5.9	8

58	Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. <i>Journal of Infection</i> , 2015 , 70, 288-98	18.9	9
57	Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. <i>Hepatology</i> , 2015 , 61, 823-33	11.2	87
56	Reliable timescale inference of HBV genotype A origin and phylodynamics. <i>Infection, Genetics and Evolution</i> , 2015 , 32, 361-9	4.5	18
55	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. <i>Infection</i> , 2014 , 42, 61-71	5.8	7
54	Understanding HIV compartments and reservoirs. <i>Current HIV/AIDS Reports</i> , 2014 , 11, 186-94	5.9	50
53	The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: evidences from literature. <i>Journal of Infection</i> , 2014 , 69, 408-10	18.9	2
52	Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2412-9	5.1	20
51	Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis. <i>Hepatology Research</i> , 2014 , 44, 1008-18	5.1	4
50	A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. <i>PLoS ONE</i> , 2014 , 9, e105853	3.7	9
49	Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage. <i>Bioinformatics</i> , 2013 , 29, 451-60	7.2	15
48	Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. <i>Journal of Infection</i> , 2013 , 67, 303-12	18.9	20
47	Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution. <i>Journal of General Virology</i> , 2013 , 94, 143-149	4.9	24
46	Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2205-9	5.1	8
45	Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. <i>Journal of Medical Virology</i> , 2013 , 85, 996-1004	19.7	16
44	Impact of pre-therapy viral load on virological response to modern first-line HAART. <i>Antiviral Therapy</i> , 2013 , 18, 867-76	1.6	31
43	The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing. <i>PLoS ONE</i> , 2013 , 8, e53603	3.7	14
42	Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes. <i>PLoS ONE</i> , 2013 , 8, e54381	3.7	1
41	Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages. <i>PLoS ONE</i> , 2013 , 8, e68076	3.7	14

40	The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype. <i>Retrovirology</i> , 2012 , 9, 15	3.6	7
39	Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage. <i>Virus Research</i> , 2012 , 168, 73-83	6.4	14
38	The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. <i>Clinical Microbiology and Infection</i> , 2012 , 18, E289-98	9.5	16
37	Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. <i>Journal of Infection</i> , 2012 , 65, 180-3	18.9	32
36	Genetic and structural analysis of HIV-1 Rev responsive element related to V38A and T18A enfuvirtide resistance mutations. <i>Intervirology</i> , 2012 , 55, 385-90	2.5	5
35	Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. <i>Antiviral Research</i> , 2012 , 93, 86-93	10.8	58
34	HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. <i>PLoS ONE</i> , 2012 , 7, e39652	3.7	74
33	Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. <i>New Microbiologica</i> , 2012 , 35, 17-25	1.1	19
32	Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase. <i>Drug Resistance Updates</i> , 2011 , 14, 141-9	23.2	14
31	Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. <i>Journal of Hepatology</i> , 2011 , 55, 587-593	13.4	68
30	Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. <i>Digestive and Liver Disease</i> , 2011 , 43, 975-83	3.3	27
29	Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage. <i>Antiviral Therapy</i> , 2011 , 16, 1035-45	1.6	20
28	HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. <i>Antiviral Research</i> , 2011 , 90, 42-53	10.8	25
27	Sentinel mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2615-23	5.1	13
26	HIV-2 A-subtype gp125cEnv mutations and their association with CCR5 and CXCR4 tropism. <i>Archives of Virology</i> , 2011 , 156, 1943-51	2.6	4
25	Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120vif signatures in the regulation of co-receptor usage. <i>Retrovirology</i> , 2011 , 8, 33	3.6	31
24	Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine. <i>ChemMedChem</i> , 2011 , 6, 2203-13	3.7	12
23	Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008. <i>Infection, Genetics and Evolution</i> , 2011 , 11, 624-32	4.5	27

22	Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 55, 336-44 ^{3.1}	29
21	Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia. <i>Digestive and Liver Disease</i> , 2010 , 42, 902-7	3.3 11
20	Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2305-18	5.1 53
19	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010 , 33, 195-206 ^{1.1}	35
18	Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 2816-23	5.9 15
17	Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs. <i>BMC Infectious Diseases</i> , 2009 , 9, 111	4 20
16	The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. <i>Journal of Hepatology</i> , 2009 , 50, 461-70	13.4 36
15	Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance. <i>Journal of Chemical Information and Modeling</i> , 2009 , 49, 1751-61	6.1 23
14	Dynamics of NRTI resistance mutations during therapy interruption. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 57-64	1.6 11
13	Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. <i>Journal of Infectious Diseases</i> , 2008 , 197, 1408-18 ⁷	34
12	HIV-1-associated dementia during HAART therapy. <i>Recent Patents on CNS Drug Discovery</i> , 2008 , 3, 23-33	16
11	Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. <i>Journal of Virology</i> , 2007 , 81, 11507-19	6.6 55
10	Therapeutic strategies towards HIV-1 infection in macrophages. <i>Antiviral Research</i> , 2006 , 71, 293-300	10.8 34
9	Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 714-22	5.1 68
8	Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. <i>Journal of Leukocyte Biology</i> , 2006 , 80, 1103-10	6.5 41
7	Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. <i>Journal of Virology</i> , 2006 , 80, 7186-98	6.6 63
6	Novel drug resistance mutations in HIV: recognition and clinical relevance. <i>AIDS Reviews</i> , 2006 , 8, 179-90 ^{1.5}	17
5	Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. <i>Journal of Medical Virology</i> , 2005 , 76, 452-8	19.7 28

4	Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 2015-25	5.9	51
3	High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. <i>Journal of Virology</i> , 2005 , 79, 10718-29	6.6	50
2	Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 55, 872-8	5.1	14
1	Characterization of Novel HIV Drug Resistance Mutations Using Clustering, Multidimensional Scaling and SVM-Based Feature Ranking. <i>Lecture Notes in Computer Science</i> , 2005 , 285-296	0.9	14